Logo image
Deconstruction of lysergic acid diethylamide
Journal article   Peer reviewed

Deconstruction of lysergic acid diethylamide

Andrian G Basargin, Andras Domokosa, Joseph J Hennessey, Isak K Aarrestad, Rohini Sambyal, Yara A Khatib, Johanna Krüger, Lee E Dunlap, Samuel J Carter, Isabella A Rebek, …
Proceedings of the National Academy of Sciences - PNAS, Vol.123(38), p.e2603412123
09/22/2026
Handle:
https://hdl.handle.net/20.500.12741/rep:14385
PMID: 42709856

Abstract

Animals Hallucinogens - chemistry Hallucinogens - pharmacology Humans Lysergic Acid Diethylamide - analogs & derivatives Lysergic Acid Diethylamide - chemistry Lysergic Acid Diethylamide - pharmacology Mice Receptor, Serotonin, 5-HT2A - metabolism Receptor, Serotonin, 5-HT2C - metabolism Serotonin 5-HT2 Receptor Agonists - chemistry Serotonin 5-HT2 Receptor Agonists - pharmacology
Of the classic psychedelics, lysergic acid diethylamide (LSD) is perhaps the best-known, but its complex chemical architecture has limited synthetic investigations aimed at generating analogues with improved safety and efficacy profiles. Here, we systematically deconstruct the tetracyclic ergoline core of LSD to create 9 simplified ergoline analogues (i.e., ergologs) and evaluate them in pharmacological assays relevant to 5-HT2A, 5-HT2B, and 5-HT2C receptor function. Our work revealed the key molecular features and minimal pharmacophore of LSD necessary to produce maximal agonism of 5-HT2A receptors and hallucinogenic behavioral effects. Furthermore, we established strategies for reducing the hallucinogenic and cardiotoxic potential of LSD and identified and as ergologs with improved safety profiles. In stark contrast to LSD, exhibits preference for activating 5-HT2C receptors over other 5-HT2 receptors and produces antipsychotic-like properties in mouse behavioral assays.
url
https://doi.org/10.1073/pnas.2603412123View
Published (Version of record) Open

Metrics

1 Record Views

Details

Logo image